Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 149% revenue increase, despite a net loss due to non-recurring items. The Q&A reveals positive progress in patient conversion and treatment completion, and management's optimism about the European market. The J-code is expected to enhance patient processing, and the revenue guidance is clear. While there is uncertainty about European approval timing, the overall sentiment is positive, driven by strong revenue growth and operational improvements.
Key Financial Performance
Net Product Revenue for Q4 2025 $3.4 million, with shipments commencing in November. This marks the beginning of PAPZIMEOS' commercial sales.
Revenue for the Year 2025 $9.7 million, an increase of $5.8 million or 149% year-over-year compared to $3.9 million in 2024. The increase was primarily driven by the commencement of PAPZIMEOS product revenue.
Research and Development Expenses Decreased by $11.7 million or 22.1% year-over-year. The decrease was primarily due to a $9.4 million reduction in costs as a result of the strategic prioritization of the company's pipeline announced in 2024.
Selling, General and Administrative Expenses Increased by $28.8 million or 69.8% year-over-year. This increase was primarily due to a $27.3 million increase in costs incurred related to PAPZIMEOS' commercial activities.
Net Loss Attributable to Common Shareholders $429.6 million or $1.37 per share for the year ended December 31, 2025. This includes two large noncash items totaling $318.5 million or $1.02 per share, related to preferred stock and warrants, which will not recur in the future.
Cash, Cash Equivalents, and Investments $100.4 million as of December 31, 2025. These funds, along with anticipated cash from PAPZIMEOS sales, are expected to fund operations through cash flow breakeven by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PAPZIMEOS Launch: PAPZIMEOS, a treatment for adult RRP, was launched commercially in Q4 2025. It achieved $3.4 million in revenue in Q4 and is expected to exceed $18 million in Q1 2026. The product has received full FDA approval with unmatched efficacy and durability, becoming the new standard of care for adult RRP.
PRGN-2009 Development: PRGN-2009, targeting HPV16 and 18 for HPV-associated cancers, is in Phase II trials for head and neck and cervical cancers. It utilizes the same AdenoVerse technology as PAPZIMEOS.
Geographic Expansion: Precigen has submitted a marketing authorization application to the EMA for PAPZIMEOS and is receiving positive feedback from European leaders. Efforts are underway to expand globally.
Revenue Growth: Revenue increased by 149% in 2025, driven by the PAPZIMEOS launch. Q1 2026 revenue is expected to exceed $18 million, showing strong uptake.
Cost Management: R&D expenses decreased by 22.1% in 2025 due to strategic pipeline prioritization. Manufacturing costs for PAPZIMEOS are now classified as inventory costs post-FDA approval.
Transition to Commercial Biotech: Precigen transitioned from an R&D-focused company to a revenue-generating commercial biotech company with the launch of PAPZIMEOS.
Pediatric RRP Trial: Plans are in place to initiate a clinical trial for PAPZIMEOS in pediatric RRP patients by Q4 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Guidance: The company does not plan to provide regular revenue guidance, which may create uncertainty for investors regarding future financial performance.
Operational Costs: Selling, general, and administrative expenses increased significantly by $28.8 million (69.8%) compared to the previous year, primarily due to commercial activities related to PAPZIMEOS. This could strain financial resources.
Net Loss: The company reported a net loss of $429.6 million for 2025, including significant noncash items. This highlights ongoing financial challenges.
Cash Reserves: The company ended 2025 with $100.4 million in cash, cash equivalents, and investments. While management believes this will fund operations through breakeven by the end of 2026, any delays or unforeseen expenses could pose risks.
Regulatory and Market Expansion: Efforts to expand PAPZIMEOS to pediatric populations and geographic markets like Europe are underway but are subject to regulatory approvals and market acceptance, which could delay or limit growth.
Pipeline Prioritization: The company reduced R&D expenses by $11.7 million due to pipeline prioritization. While this reduces costs, it may limit future innovation and diversification.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects Q1 2026 revenue to exceed $18 million, driven by the strong commercial uptake of PAPZIMEOS. This represents a significant increase from Q4 2025 revenue of $3.4 million.
Market Trends and Product Adoption: PAPZIMEOS is experiencing robust adoption across major medical centers, community practices, and a range of patient severities. The company anticipates continued institutional activation and significant utilization within community practices.
Regulatory and Reimbursement Developments: The assignment of a permanent J-code for PAPZIMEOS, effective April 1, is expected to support continued growth and adoption.
Geographic Expansion: Plans are underway for geographic expansion, including the validation of a marketing authorization application to the EMA for PAPZIMEOS. Positive feedback has been received from European leaders regarding the new medical standard of care.
Pipeline Development: The company plans to initiate a clinical trial for PAPZIMEOS in the pediatric RRP population in Q4 2026. Additionally, the PRGN-2009 program, targeting HPV16 and 18-associated cancers, is progressing in Phase II trials.
Financial Outlook: The company expects to achieve cash flow breakeven by the end of 2026, supported by anticipated PAPZIMEOS sales and current cash reserves.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you help us think about how you are planning the flow of patients from the hub to receiving reimbursed drug? Do you expect the majority of the 300 patients to ultimately get reimbursed treatment? And in what kind of time frame?
A:The company is seeing significant conversion of patients from their hub and other sources. The goal is to convert the vast majority of patients to treatment. The speed of conversion varies by patient and institution, with prior authorization taking a matter of weeks once all pieces are in place. Progress has been made in activating IDNs and payer coverage.
Q:Are you now at the point where patients are starting to get their second dose in the treatment regimen? Can you give any color about the proportion of patients eligible or getting the second treatment?
A:Patients are moving through all their treatments, including second doses. Some patients who started last year have completed their treatment. The process is continuous, with new patients entering the hub as others progress through treatment.
Q:How is the J-code helping in terms of adding more patients this quarter and preparing for the next quarter?
A:The J-code simplifies the workflow and billing process for providers and payers, streamlining the administrative process and increasing the speed of patient processing. This is expected to help in Q2 and beyond.
Q:What is the status of your discussions with the European regulatory body regarding the MAA and potential European launch? Do you expect approval in the first half of 2027?
A:The EMA application is under review, and the company is excited about the enthusiasm from European physicians. Approval timing is uncertain and depends on the European authorities. The company will share updates when available.
Q:Can you clarify if the $18 million revenue guidance includes collaboration and service revenues in addition to PAPZIMEOS product revenue?
A:The $18 million revenue guidance includes only PAPZIMEOS product revenue and no other revenue.
Q:Is there a stocking effect in the $18 million projection compared to patients who have received PAPZIMEOS? Can you talk about the number of doctors actively prescribing PAPZIMEOS and the conversion rate from your patient hub compared to the academic hub?
A:There is very little stocking effect, with most institutions ordering one vial at a time. The number of prescribers is increasing, and conversion is happening from both the company’s hub and other hubs, with significant contributions from both.
Q:What differentiates community sites that become repeat prescribers versus those that adopt a wait-and-see approach?
A:Community sites that become repeat prescribers benefit from low-cost logistics solutions and just-in-time shipments, which eliminate the need for cold storage. The initial experience with community uptake has been very positive.
Q:Can you provide color on the current channel mix of U.S. payers and how we should think about gross-to-net cadence for the year?
A:The payer mix is approximately 60-65% commercial, with the rest being Medicare, Medicaid, and government channels. Gross-to-net is expected to be in the high teens to low 20s, consistent with historical guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the expected approval timing for the European launch, stating that it depends on the European authorities and did not provide a clear timeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA approval
Helen
Medicare Medicaid
PAPZIMEOS launch
PAPZIMEOS sale
activation
activity date
adult RRP
advancement
approval PAPZIMEOS
brand
care line
cause RRP
center community
community practice
consensus paper
coverage
field
health care
indicator
inventory
investor
label
launch progress
launch trajectory
life
line treatment
momentum
noncash item
paper PAPZIMEOS
product
progress launch
ramp
research development
utilization
PGEN Transcript
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with a 149% revenue increase, despite a net loss due to non-recurring items. The Q&A reveals positive progress in patient conversion and treatment completion, and management's optimism about the European market. The J-code is expected to enhance patient processing, and the revenue guidance is clear. While there is uncertainty about European approval timing, the overall sentiment is positive, driven by strong revenue growth and operational improvements.
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Unknown3-19
The earnings call reflects mixed signals: strong cash position and anticipated demand for PRGN-2012 suggest positive sentiment. However, increased net loss, operational risks, and competitive pressures temper optimism. The Q&A highlights management's cautious communication about FDA interactions and market capture, which adds uncertainty. Considering these factors, the stock price is expected to remain stable.
PGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
